AttendMe Owl Logo
AttendMe
Evidence Evolution
Critical CareCritical Care

How This Evidence Evolved

Vasopressor Selection in Septic Shock

Beyond the dopamine era

4.3

Timeline

Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

VASST tested low-dose vasopressin versus additional norepinephrine in patients with septic shock already receiving catecholamine vasopressors. Overall 28-day mortality did not differ significantly (35.4% vs 39.3%). A prospectively defined less-severe-shock stratum had mortality of 26.5% versus 35.7% (P=.05), but the test for heterogeneity between severity strata was not significant (P=.10). This distinction matters: a subgroup signal does not establish that treatment effects differ by shock severity.
Proof

Landmark RCTs and pivotal trials that established the evidence base

SOAP II randomized 1,679 patients with shock to dopamine or norepinephrine. Overall 28-day mortality did not differ significantly, but arrhythmic events were more common with dopamine (24.1% vs 12.4%; P<.001). A cardiogenic-shock subgroup also had higher mortality with dopamine. A subsequent meta-analysis analyzed observational studies and randomized trials separately; across its six randomized trials, dopamine was associated with higher mortality and more arrhythmias. These comparisons underpin the preference for norepinephrine while keeping the overall SOAP II mortality result distinct from its subgroup findings.
Extension

Follow-up studies, subgroup analyses, and real-world validation

With norepinephrine established as first-line, research turned to adjunctive agents for refractory shock. In ATHOS-3 (2017; 321 patients with vasodilatory shock on >0.2 μg/kg/min of norepinephrine or equivalent), angiotensin II achieved a mean arterial pressure response at hour 3 in 69.9% vs 23.4% with placebo (OR 7.95, 95% CI 4.76-13.3; P<0.001). The VANISH trial (2016; 409 patients) compared early vasopressin with norepinephrine: 57.0% vs 59.2% of survivors never developed kidney failure (difference -2.3%, 95% CI -13.0% to 8.5%), but renal replacement therapy was used less with vasopressin (25.4% vs 35.3%; difference -9.9%, 95% CI -19.3% to -0.6%). The VANCS trial (2017; 300 patients) compared vasopressin with norepinephrine in vasoplegic shock after cardiac surgery: death or severe complications within 30 days occurred in 32% vs 49% (unadjusted HR 0.55, 95% CI 0.38-0.80; P=0.0014). These trials expanded the armamentarium beyond catecholamines and supported a multi-agent approach for refractory shock.
Guidelines

Integration into clinical practice guidelines and recommendations

SSC 2021 strongly recommends norepinephrine first-line in septic shock. For inadequate MAP on norepinephrine, it weakly suggests adding vasopressin rather than escalating norepinephrine. If norepinephrine is unavailable, dopamine or epinephrine may be alternatives, with attention to arrhythmia risk. KDIGO 2012 (2013 summary) recommends against low-dose dopamine to prevent or treat AKI (1A). Angiotensin II should not be first-line; the panel describes a possible adjunctive role, while judging the evidence and clinical safety experience limited.
Surviving Sepsis Campaign 2021

Norepinephrine first-line (strong); add vasopressin for inadequate MAP rather than escalating norepinephrine (weak).

Surviving Sepsis Campaign 2021

Suggest adding vasopressin rather than escalating norepinephrine for inadequate MAP (weak recommendation); vasopressin is usually fixed at 0.03 U/min.

KDIGO 2012 AKI guideline — Part 1 summary

Do not use low-dose dopamine to prevent or treat AKI (1A).

Now

Current standard of care and ongoing research directions

SSC recommends norepinephrine first-line and describes starting vasopressin when norepinephrine is around 0.25–0.5 μg/kg/min; the threshold remains uncertain. It supports short-term peripheral vasopressors to avoid delaying pressure restoration and suggests IV corticosteroids for ongoing vasopressor requirements. Angiotensin II has physiological efficacy but limited outcome evidence. VITAMINS and VICTAS did not improve their primary outcomes with vitamin C-hydrocortisone-thiamine; VICTAS was administratively terminated early and may have been underpowered. Timing and initiation thresholds remain questions.

Landmark Trials in This Story

VASST2008Landmark

Vasopressin versus norepinephrine infusion in patients with septic shock

28-day mortality 35.4% vs 39.3%, p=0.26

New England journal of medicineRCTN=778
SOAP II2010Landmark

Comparison of dopamine and norepinephrine in the treatment of shock

28-day mortality 52.5% vs 48.5%, p=0.10; arrhythmias 24.1% vs 12.4%, p<0.001

New England journal of medicineRCTN=1,679
De Backer 20122012

Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis.

28-day mortality (or closest estimate) in randomised trials: dopamine vs norepinephrine RR 1.12 (CI 1.01-1.20; p=.035); arrhythmias (2 trials): RR 2.34 (CI 1.46-3.77; p=.001)

Crit Care MedMeta-analysis of 5 observational studies (1,360 patients) and 6 randomised trials (1,408 patients)N=2,768
ATHOS-32017Landmark

Angiotensin II for the Treatment of Vasodilatory Shock

MAP response at hour 3: 69.9% vs 23.4%, p<0.001

New England journal of medicineRCTN=344
VANISH2016

Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial

Kidney failure-free days: no significant difference; RRT: vasopressin 25.4% vs norepinephrine 35.3%

JAMARCTN=409
VANCS2017

Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial.

Death or severe complications (stroke, ventilation >48 h, deep sternal wound infection, reoperation or acute renal failure) within 30 days: vasopressin 32% (n=149) vs norepinephrine 49% (n=151) (unadjusted HR 0.55, 95% CI 0.38-0.80; P=0.0014)

AnesthesiologyProspective, randomised, double-blind trial at the Heart Institute (300 of 330 randomised received study drug)N=330
VICTAS2021

Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial.

Ventilator- and vasopressor-free days within 30 days: combination 25 vs placebo 26 days (median difference -1 day, 95% CI -4 to 2; P=.85).

JAMAMulticenter randomized double-blind placebo-controlled trial, administratively terminated earlyN=501
VITAMINS2020

Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial.

Time alive and free of vasopressors to day 7: combination 122.1 h vs hydrocortisone alone 124.6 h; paired median difference −0.6 h (95% CI −8.3 to 7.2; P=.83).

JAMAMulticenter open-label randomized trialN=216

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

Why is norepinephrine preferred over dopamine?+
In SOAP II (1679 patients), dopamine caused more arrhythmic events than norepinephrine (24.1% vs 12.4%, P<0.001) and higher 28-day mortality in the cardiogenic shock subgroup (P=0.03), with no overall mortality difference. A meta-analysis of six RCTs in septic shock linked dopamine to higher mortality (RR 1.12, CI 1.01-1.20). The Surviving Sepsis Campaign 2021 recommends norepinephrine as the first-line agent over other vasopressors.
When should vasopressin be added?+
The Surviving Sepsis Campaign 2021 suggests adding vasopressin rather than escalating norepinephrine when MAP is inadequate; in the panel's practice it is usually started at norepinephrine 0.25-0.5 μg/kg/min and given at a fixed 0.03 units/min. In VANISH, early vasopressin did not improve kidney failure-free days but cut renal replacement therapy (25.4% vs 35.3%); VANISH does not support it replacing norepinephrine first-line.
What role does angiotensin II play?+
ATHOS-3 tested angiotensin II versus placebo in vasodilatory shock despite high-dose conventional vasopressors. At 3 hours, its MAP-response endpoint occurred in 69.9% versus 23.4% (P<.001). Day-28 mortality was 46% versus 54% (HR 0.78, 95% CI 0.57–1.07; P=.12). SSC describes a possible adjunctive role rather than first-line use, given very-low-quality evidence and limited safety experience.
Can vasopressors be started through a peripheral IV?+
Yes. The Surviving Sepsis Campaign 2021 suggests starting vasopressors peripherally to restore MAP rather than delaying initiation until central venous access is secured (weak recommendation, very low quality of evidence), for a short period only and in a vein in or proximal to the antecubital fossa. A systematic review cited by the panel found extravasation in 3.4% (95% CI 2.5-4.7%) of patients, with no reported tissue necrosis or limb ischaemia.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026